Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Members of the Chemical Biology Program approach biological problems with an open mind in terms of the exact chemical solution that we will pursue, basing our decisions on the specific biological and/or clinical context.
We are developing many different classes of small molecule modulators, including covalent and allosteric inhibitors, and are investigating their mechanisms of action. We also work on inventing new small molecule-based pharmacologic modalities, like the
degrader molecules (PROTACs and degronimids).
Several labs in our program are using small molecule inhibitors and/or degraders to pursue different molecular targets and strategies: